Gabexate
 | |
| Systematic (IUPAC) name | |
|---|---|
| ethyl 4-[6-(diaminomethylideneamino)hexanoyloxy]benzoate | |
| Clinical data | |
| AHFS/Drugs.com | International Drug Names |
| Identifiers | |
39492-01-8  | |
| None | |
| PubChem | CID 3447 |
| ChemSpider |
3329  |
| UNII |
4V7M9137X9 |
| KEGG |
D08004 |
| ChEMBL |
CHEMBL87563 |
| Chemical data | |
| Formula | C16H23N3O4 |
| 311.37 g/mol | |
|
SMILES
| |
| |
| (what is this?) (verify) | |
Gabexate is a serine protease inhibitor which is used therapeutically (as gabexate mesilate) in the treatment of pancreatitis, disseminated intravascular coagulation,[1] and as a regional anticoagulant for haemodialysis.[2]
References
- ↑ Yuksel M, Okajima K, Uchiba M, Okabe H (2003). "Gabexate mesilate, a synthetic protease inhibitor, inhibits lipopolysaccharide-induced tumor necrosis factor-alpha production by inhibiting activation of both nuclear factor-kappaB and activator protein-1 in human monocytes". J. Pharmacol. Exp. Ther. 305 (1): 298–305. doi:10.1124/jpet.102.041988. PMID 12649382.
- ↑ Cavallini G, Tittobello A, Frulloni L, Masci E, Mariana A, Di Francesco V (1996). "Gabexate for the prevention of pancreatic damage related to endoscopic retrograde cholangiopancreatography. Gabexate in digestive endoscopy--Italian Group". N. Engl. J. Med. 335 (13): 919–23. doi:10.1056/NEJM199609263351302. PMID 8786777.